Dynavax Technologies (NASDAQ:DVAX) Upgraded to “Strong-Buy” at Wall Street Zen

Dynavax Technologies (NASDAQ:DVAX) was upgraded by analysts at Wall Street Zen to a “strong-buy” rating in a research note issued on Saturday.

Several other equities analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st. William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Dynavax Technologies has an average rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $15.50 on Friday. Dynavax Technologies has a one year low of $9.20 and a one year high of $15.73. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -41.89 and a beta of 0.97. The company has a 50-day simple moving average of $14.40 and a 200-day simple moving average of $11.81. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62.

Insider Buying and Selling at Dynavax Technologies

In other news, COO David F. Novack sold 114,000 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the transaction, the chief operating officer owned 63,344 shares in the company, valued at $990,700.16. This trade represents a 64.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.98% of the stock is currently owned by company insiders.

Institutional Trading of Dynavax Technologies

A number of institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S purchased a new position in Dynavax Technologies in the fourth quarter valued at about $34,000. Global Retirement Partners LLC purchased a new stake in shares of Dynavax Technologies during the 4th quarter worth approximately $43,000. Leonteq Securities AG acquired a new stake in shares of Dynavax Technologies in the 4th quarter worth approximately $47,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Dynavax Technologies by 3,193.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,129 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 3,034 shares during the period. Finally, Hantz Financial Services Inc. increased its stake in Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,710 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.